{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T03:13:01Z","timestamp":1768965181132,"version":"3.49.0"},"reference-count":42,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2024,9,20]],"date-time":"2024-09-20T00:00:00Z","timestamp":1726790400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,3,10]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Objective<\/jats:title>\n                  <jats:p>The aim of this study was to determine the efficacy of plerixafor for hematopoietic stem cell (HSC) mobilization prior to autologous stem cell transplantation (aSCT) for patients with multiple myeloma (MM) and various lymphomas, using an oncologist-guided HSC collection goal and markers of cell viability.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>A retrospective chart review of all aSCT patients at Yale New Haven Hospital between 2017 and 2021 who met diagnostic criteria for MM, non-Hodgkin, or Hodgkin lymphoma (n = 382) was undertaken. Logistic regression evaluated plerixafor\u2019s effect on meeting the individual\u2019s HSC goal. The use of t-tests determined plerixafor\u2019s relationship to HSC yield and analysis of variance testing assessed its effect on cell viability.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Mobilization with granulocyte colony\u2013stimulating factor (G-CSF) and plerixafor (odds ratio [OR] = 0.08; P &amp;lt; .05) relative to G-CSF alone was negatively associated with meeting the individual\u2019s HSC goal. Diffuse large B-cell lymphoma in patients mobilized with plerixafor yielded fewer HSCs than those without plerixafor (t = \u20132.78; P = .03). Mobilization regimen (P = .13) had no association with HSC viability. Mobilization failure with plerixafor was rare but occurred in patients with multiple risk factors, including exposure to several rounds of HSC-affecting chemotherapy.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>Plerixafor is effective across multiple diagnoses using an oncologist-driven HSC collection endpoint. Its association with mobilization failure is likely attributable to its use in patients predicted to be poor mobilizers.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/labmed\/lmae080","type":"journal-article","created":{"date-parts":[[2024,9,20]],"date-time":"2024-09-20T22:05:27Z","timestamp":1726869927000},"page":"187-194","source":"Crossref","is-referenced-by-count":1,"title":["The effect of plerixafor on autologous stem cell mobilization, cell viability, and apheresis challenges"],"prefix":"10.1093","volume":"56","author":[{"given":"Christian J","family":"Puzo","sequence":"first","affiliation":[{"name":"Yale School of Medicine , New Haven, CT ,","place":["US"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philippa","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine, Yale School of Medicine , New Haven, CT ,","place":["US"]},{"name":"Department of Pathology, Yale School of Medicine , New Haven, CT ,","place":["US"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher A","family":"Tormey","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine, Yale School of Medicine , New Haven, CT ,","place":["US"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2372-3653","authenticated-orcid":false,"given":"Alexa J","family":"Siddon","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine, Yale School of Medicine , New Haven, CT ,","place":["US"]},{"name":"Department of Pathology, Yale School of Medicine , New Haven, CT ,","place":["US"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2024,9,20]]},"reference":[{"issue":"3","key":"2025031011215578000_CIT0001","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1016\/j.bbmt.2013.10.013","article-title":"Optimizing autologous stem cell mobilization strategies to improve patient outcomes: consensus guidelines and recommendations","volume":"20","author":"Giralt","year":"2014","journal-title":"Biol Blood Marrow Transplant."},{"key":"2025031011215578000_CIT0002","doi-asserted-by":"publisher","first-page":"403","DOI":"10.2147\/JBM.S307520","article-title":"Use of plerixafor for stem cell mobilization in the setting of autologous and allogeneic stem cell transplantations: an update","volume":"12","author":"Bilgin","year":"2021","journal-title":"J Blood Med"},{"issue":"8","key":"2025031011215578000_CIT0003","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1038\/sj.bmt.1705298","article-title":"Poor mobilization is an independent prognostic factor in patients with malignant lymphomas treated by peripheral blood stem cell transplantation","volume":"37","author":"Pavone","year":"2006","journal-title":"Bone Marrow Transplant."},{"issue":"9","key":"2025031011215578000_CIT0004","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1016\/j.bbmt.2008.07.004","article-title":"Impact of mobilization and remobilization strategies on achieving sufficient stem cell yields for autologous transplantation","volume":"14","author":"Pusic","year":"2008","journal-title":"Biol Blood Marrow Transplant."},{"issue":"1","key":"2025031011215578000_CIT0005","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.transci.2015.05.011","article-title":"Optimizing mobilization strategies in difficult-to-mobilize patients: the role of plerixafor","volume":"53","author":"Goker","year":"2015","journal-title":"Transfus Apher Sci."},{"issue":"3","key":"2025031011215578000_CIT0006","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1038\/bmt.2011.82","article-title":"Proposed definition of \u2018poor mobilizer\u2019 in lymphoma and multiple myeloma: an analytic hierarchy process by ad hoc working group Gruppo ItalianoTrapianto di Midollo Osseo","volume":"47","author":"Olivieri","year":"2012","journal-title":"Bone Marrow Transplant."},{"issue":"3","key":"2025031011215578000_CIT0007","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1016\/j.pharmthera.2010.08.009","article-title":"Recent advances on the use of the CXCR4 antagonist plerixafor (AMD3100, Mozobil\u2122) and potential of other CXCR4 antagonists as stem cell mobilizers","volume":"128","author":"De Clercq","year":"2010","journal-title":"Pharmacol Ther."},{"issue":"23","key":"2025031011215578000_CIT0008","doi-asserted-by":"publisher","first-page":"5720","DOI":"10.1182\/blood-2008-08-174946","article-title":"Plerixafor and G-CSF versus placebo and G-CSF to mobilize hematopoietic stem cells for autologous stem cell transplantation in patients with multiple myeloma","volume":"113","author":"DiPersio","year":"2009","journal-title":"Blood."},{"issue":"28","key":"2025031011215578000_CIT0009","doi-asserted-by":"publisher","first-page":"4767","DOI":"10.1200\/JCO.2008.20.7209","article-title":"Phase III prospective randomized double-blind placebo-controlled trial of plerixafor plus granulocyte colony-stimulating factor compared with placebo plus granulocyte colony-stimulating factor for autologous stem-cell mobilization and transplantation for patients with non-Hodgkin\u2019s lymphoma","volume":"27","author":"DiPersio","year":"2009","journal-title":"J Clin Oncol."},{"issue":"1","key":"2025031011215578000_CIT0010","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.clml.2021.07.030","article-title":"Multiple myeloma: risk adapted use of plerixafor for stem cell mobilization prior to autologous stem cell transplantation is effective and cost efficient","volume":"22","author":"Prakash","year":"2022","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"12","key":"2025031011215578000_CIT0011","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.1002\/ajh.23561","article-title":"Safety and efficacy of upfront plerixafor + G-CSF versus placebo + G-CSF for mobilization of CD34(+) hematopoietic progenitor cells in patients \u226560 and &lt;60 years of age with non-Hodgkin\u2019s lymphoma or multiple myeloma","volume":"88","author":"Micallef","year":"2013","journal-title":"Am J Hematol."},{"issue":"6","key":"2025031011215578000_CIT0012","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1038\/bmt.2012.219","article-title":"Plerixafor and G-CSF for autologous stem cell mobilization in patients with NHL, Hodgkin\u2019s lymphoma and multiple myeloma: results from the Expanded Access program","volume":"48","author":"Shaughnessy","year":"2013","journal-title":"Bone Marrow Transplant."},{"issue":"11","key":"2025031011215578000_CIT0013","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.1016\/j.bbmt.2008.08.011","article-title":"A phase II study of plerixafor (AMD3100) plus G-CSF for autologous hematopoietic progenitor cell mobilization in patients with Hodgkin lymphoma","volume":"14","author":"Cashen","year":"2008","journal-title":"Biol Blood Marrow Transplant."},{"issue":"8","key":"2025031011215578000_CIT0014","doi-asserted-by":"publisher","first-page":"2015","DOI":"10.1111\/trf.12594","article-title":"Efficacy of just-in-time plerixafor rescue for Hodgkin\u2019s lymphoma patients with poor peripheral blood stem cell mobilization","volume":"54","author":"Yuan","year":"2014","journal-title":"Transfusion."},{"issue":"6","key":"2025031011215578000_CIT0015","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1089\/scd.2004.13.598","article-title":"What is the optimum number of CD34+ peripheral blood stem cells for an autologous transplant","volume":"13","author":"Jillella","year":"2004","journal-title":"Stem Cells Dev."},{"issue":"2","key":"2025031011215578000_CIT0016","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1053\/bbmt.1998.v4.pm9763111","article-title":"Effect of CD34+ peripheral blood progenitor cell dose on hematopoietic recovery","volume":"4","author":"Shpall","year":"1998","journal-title":"Biol Blood Marrow Transplant."},{"key":"2025031011215578000_CIT0017","doi-asserted-by":"publisher","first-page":"517561","DOI":"10.1155\/2011\/517561","article-title":"Long-term outcome after autologous stem cell transplantation with adequate peripheral blood stem cell mobilization using plerixafor and G-CSF in poor mobilizer lymphoma and myeloma patients","volume":"2011","author":"Moreb","year":"2011","journal-title":"Adv Hematol"},{"issue":"2","key":"2025031011215578000_CIT0018","doi-asserted-by":"publisher","first-page":"172","DOI":"10.3324\/haematol.2012.071456","article-title":"Plerixafor and granulocyte colony-stimulating factor for first-line steady-state autologous peripheral blood stem cell mobilization in lymphoma and multiple myeloma: results of the prospective PREDICT trial","volume":"98","author":"Russell","year":"2013","journal-title":"Haematologica."},{"issue":"4","key":"2025031011215578000_CIT0019","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1038\/sj.bmt.1705908","article-title":"AMD3100 plus G-CSF can successfully mobilize CD34+ cells from non-Hodgkin\u2019s lymphoma, Hodgkin\u2019s disease and multiple myeloma patients previously failing mobilization with chemotherapy and\/or cytokine treatment: compassionate use data","volume":"41","author":"Calandra","year":"2008","journal-title":"Bone Marrow Transplant."},{"issue":"2","key":"2025031011215578000_CIT0020","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/j.transci.2013.02.032","article-title":"Use of plerixafor in patients that show failure of peripheral blood stem cell mobilization with G-CSF. Experience of three Dutch centers","volume":"48","author":"Bilgin","year":"2013","journal-title":"Transfus Apher Sci."},{"issue":"2","key":"2025031011215578000_CIT0021","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1038\/s41409-020-01033-8","article-title":"Autologous stem-cell collection following VTD or VRD induction therapy in multiple myeloma: a single-center experience","volume":"56","author":"Laurent","year":"2021","journal-title":"Bone Marrow Transplant."},{"issue":"17","key":"2025031011215578000_CIT0022","doi-asserted-by":"publisher","first-page":"4530","DOI":"10.1182\/blood-2011-06-318220","article-title":"How I treat patients who mobilize hematopoietic stem cells poorly","volume":"118","author":"To","year":"2011","journal-title":"Blood."},{"issue":"3","key":"2025031011215578000_CIT0023","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1038\/bmt.2015.236","article-title":"A randomized phase II study of stem cell mobilization with cyclophosphamide+G-CSF or G-CSF alone after lenalidomide-based induction in multiple myeloma","volume":"51","author":"Silvennoinen","year":"2016","journal-title":"Bone Marrow Transplant."},{"issue":"11","key":"2025031011215578000_CIT0024","doi-asserted-by":"publisher","first-page":"5513","DOI":"10.1182\/blood.v106.11.5513.5513","article-title":"RICE\/ICE is an effective PBSC mobilising regime in patients with aggressive lymphoma","volume":"106","author":"Wilson","year":"2005","journal-title":"Blood."},{"key":"2025031011215578000_CIT0025","doi-asserted-by":"publisher","first-page":"825550","DOI":"10.3389\/fonc.2022.825550","article-title":"High efficacy of stem cell mobilization with etoposide+cytarabine plus G-CSF in patients with multiple myeloma","volume":"12","author":"Zhu","year":"2022","journal-title":"Front Oncol."},{"issue":"6","key":"2025031011215578000_CIT0026","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1016\/j.transci.2017.11.017","article-title":"Management of mobilization failure in 2017","volume":"56","author":"Namdaroglu","year":"2017","journal-title":"Transfus Apher Sci."},{"issue":"3","key":"2025031011215578000_CIT0027","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/j.transci.2013.04.028","article-title":"Predicting the successful peripheral blood stem cell harvesting","volume":"48","author":"Demiriz","year":"2013","journal-title":"Transfus Apher Sci."},{"key":"2025031011215578000_CIT0028","doi-asserted-by":"publisher","first-page":"A3.B.1","DOI":"10.1002\/0471142735.ima03bs111","article-title":"Trypan blue exclusion test of cell viability","volume":"111","author":"Strober","year":"2015","journal-title":"Curr Protoc Immunol"},{"issue":"5","key":"2025031011215578000_CIT0029","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1007\/s12185-018-2505-4","article-title":"Plerixafor for mobilization and collection of haematopoietic stem cells for autologous transplantation in Japanese patients with non-Hodgkin lymphoma: a randomized phase 2 study","volume":"108","author":"Matsue","year":"2018","journal-title":"Int J Hematol."},{"issue":"1","key":"2025031011215578000_CIT0030","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1111\/trf.14426","article-title":"Plerixafor and granulocyte-colony-stimulating factor for mobilization of hematopoietic stem cells for autologous transplantation in Chinese patients with non-Hodgkin\u2019s lymphoma: a randomized phase 3 study","volume":"58","author":"Zhu","year":"2018","journal-title":"Transfusion."},{"issue":"1","key":"2025031011215578000_CIT0031","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1186\/s13287-022-02802-6","article-title":"Efficacy of hematopoietic stem cell mobilization regimens in patients with hematological malignancies: a systematic review and network meta-analysis of randomized controlled trials","volume":"13","author":"Luo","year":"2022","journal-title":"Stem Cell Res Ther."},{"issue":"10","key":"2025031011215578000_CIT0032","doi-asserted-by":"publisher","first-page":"1564","DOI":"10.1016\/j.bbmt.2012.05.017","article-title":"Plerixafor plus granulocyte colony-stimulating factor versus placebo plus granulocyte colony-stimulating factor for mobilization of CD34(+) hematopoietic stem cells in patients with multiple myeloma and low peripheral blood CD34(+) cell count: results of a subset analysis of a randomized trial","volume":"18","author":"Nademanee","year":"2012","journal-title":"Biol Blood Marrow Transplant."},{"issue":"7","key":"2025031011215578000_CIT0033","doi-asserted-by":"publisher","first-page":"590.e1","DOI":"10.1016\/j.jtct.2021.04.016","article-title":"Stem cell mobilization in multiple myeloma: comparing safety and efficacy of cyclophosphamide +\/- plerixafor versus granulocyte colony-stimulating factor +\/- plerixafor in the lenalidomide era","volume":"27","author":"Johnsrud","year":"2021","journal-title":"Transplant Cell Ther"},{"issue":"5","key":"2025031011215578000_CIT0034","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1007\/s00277-023-05170-0","article-title":"Stem cell mobilization in multiple myeloma: challenges, strategies, and current developments","volume":"102","author":"Wei","year":"2023","journal-title":"Ann Hematol."},{"issue":"9","key":"2025031011215578000_CIT0035","doi-asserted-by":"publisher","first-page":"1729","DOI":"10.1182\/blood-2009-04-205013","article-title":"Mobilization in myeloma revisited: IMWG consensus perspectives on stem cell collection following initial therapy with thalidomide-, lenalidomide-, or bortezomib-containing regimens","volume":"114","author":"Kumar","year":"2009","journal-title":"Blood."},{"issue":"Supplement 1","key":"2025031011215578000_CIT0036","doi-asserted-by":"publisher","first-page":"3886","DOI":"10.1182\/blood-2021-149499","article-title":"Impact of daratumumab-containing induction on stem cell mobilization and collection, engraftment and hospitalization parameters among multiple myeloma patients undergoing autologous stem cell transplantation","volume":"138","author":"Eleutherakis Papaiakovou","year":"2021","journal-title":"Blood."},{"issue":"6","key":"2025031011215578000_CIT0037","doi-asserted-by":"publisher","first-page":"626","DOI":"10.15537\/smj.2022.43.6.20210912","article-title":"Autologous peripheral blood stem cell mobilization and collection in patients with lymphoma and multiple myeloma: a single-center experience using the plerixa for pre-emptive approach","volume":"43","author":"Alsaeed","year":"2022","journal-title":"Saudi Med J."},{"issue":"7","key":"2025031011215578000_CIT0038","doi-asserted-by":"publisher","first-page":"823","DOI":"10.3109\/14653249.2012.681042","article-title":"Predictive factors for poor peripheral blood stem cell mobilization and peak CD34(+) cell count to guide pre-emptive or immediate rescue mobilization","volume":"14","author":"Sancho","year":"2012","journal-title":"Cytotherapy."},{"issue":"7","key":"2025031011215578000_CIT0039","doi-asserted-by":"publisher","first-page":"886","DOI":"10.1038\/bmt.2014.330","article-title":"Mobilized peripheral blood grafts include more than hematopoietic stem cells: the immunological perspective","volume":"50","author":"Saraceni","year":"2015","journal-title":"Bone Marrow Transplant."},{"issue":"7","key":"2025031011215578000_CIT0040","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1016\/j.jcyt.2023.02.006","article-title":"Benefits of plerixafor for mobilization of peripheral blood stem cells prior to autologous transplantation: a dual-center retrospective cohort study","volume":"25","author":"Nakamura","year":"2023","journal-title":"Cytotherapy."},{"issue":"3","key":"2025031011215578000_CIT0041","doi-asserted-by":"publisher","first-page":"103130","DOI":"10.1016\/j.transci.2021.103130","article-title":"Engraftment after autologous hematopoietic stem cell transplantation in patients mobilized with plerixafor: a retrospective, multicenter study of a large series of patients","volume":"60","author":"Antelo","year":"2021","journal-title":"Transfus Apher Sci."},{"issue":"3","key":"2025031011215578000_CIT0042","doi-asserted-by":"publisher","first-page":"608","DOI":"10.3390\/cancers15030608","article-title":"Poor mobilizers in lymphoma but not myeloma patients had significantly poorer progression-free survival after autologous stem cell transplantation: results of a large retrospective, single-center observational study","volume":"15","author":"Steiner","year":"2023","journal-title":"Cancers (Basel)"}],"container-title":["Laboratory Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/labmed\/article-pdf\/56\/2\/187\/59215220\/lmae080.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/labmed\/article-pdf\/56\/2\/187\/59215220\/lmae080.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,10]],"date-time":"2025-03-10T11:22:06Z","timestamp":1741605726000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/labmed\/article\/56\/2\/187\/7762939"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,20]]},"references-count":42,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2024,9,20]]},"published-print":{"date-parts":[[2025,3,10]]}},"URL":"https:\/\/doi.org\/10.1093\/labmed\/lmae080","relation":{},"ISSN":["0007-5027","1943-7730"],"issn-type":[{"value":"0007-5027","type":"print"},{"value":"1943-7730","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,3]]},"published":{"date-parts":[[2024,9,20]]}}}